Bloki podsumowujące i pełny artykuł są po angielsku dla spójności redakcyjnej. Tytuł, opis i to wprowadzenie są zlokalizowane.

Amycretin: Unimolecular GLP-1 + Amylin Dual Agonist Entering Phase 3

Amycretin is a single peptide molecule that simultaneously activates both the GLP-1 receptor and the amylin receptor — making it the first unimolecular GLP-1/amylin co-agonist to reach Phase 3. Phase 2 subcutaneous data showing up to 24% body weight reduction at 36 weeks placed it among the highest weight-loss signals ever reported in an obesity drug trial.

Why "Unimolecular" Matters

The distinction from CagriSema is important. CagriSema is two separate molecules (cagrilintide + semaglutide) co-administered. Amycretin is one molecule engineered to carry both receptor activities:

• Fewer drug-drug interaction variables.
• Simpler pharmacokinetic profile — one half-life, one dosing schedule.
• One injection rather than what would otherwise be a combination product.

Both approaches hit the same two receptors. The unimolecular design is a formulation and development bet, not necessarily a clinical superiority claim.

How GLP-1 + Amylin Differs from GLP-1 + GIP

Users often conflate amycretin with tirzepatide because both are "single molecule + two receptors." The receptor families are different:

• Tirzepatide → GLP-1 receptor + GIP receptor (both incretin family)
• Amycretin → GLP-1 receptor + amylin receptor (different hormone family, different satiety pathway)

Amylin signals through a receptor complex (calcitonin receptor + RAMP) that is distinct from GLP-1 signaling pathways. The downstream satiety and gastric-emptying effects complement rather than duplicate GLP-1.

Phase 2 Data Summary

Subcutaneous amycretin in a Phase 1b/2a trial showed:

• Up to 24% mean body weight reduction at 36 weeks — the highest single Phase 2 signal reported in obesity at time of publication (The Lancet, 2025).

An oral formulation also entered trials, with Phase 2 data showing approximately 13.1% weight reduction at 12 weeks — notable for an oral agent, though the longer-term trajectory needs Phase 3 to characterize fully.

Phase 3 programs were initiated in Q1 2026.

What Phase 2 Data Can and Cannot Tell You

A single Phase 2 trial, even a well-run one, sets a hypothesis — not a conclusion:

1. Sample sizes are smaller — effect estimates are less stable than Phase 3.
2. Selection effects — Phase 2 populations may not reflect Phase 3 breadth.
3. 24% is a headline; durability, safety profile, and dropout rates matter as much.

The 24% figure is scientifically credible and warrants Phase 3 urgency, but should not be read as a guaranteed Phase 3 outcome.

Safety Themes

Amycretin Phase 2 discussions have covered:

• GI tolerability consistent with dual GLP-1/amylin satiety signaling.
• Nausea and vomiting — expected class effects on dose titration.
• Standard GLP-1 class monitoring themes (pancreatitis, gallbladder).

No unusual safety signals distinguished it from the class in Phase 2 reporting.

Where It Fits in the Pipeline Landscape

Compound	Mechanism	Form	Status (2026)
Semaglutide	GLP-1	Weekly injection / oral	Approved
Tirzepatide	GLP-1 + GIP	Weekly injection	Approved
CagriSema	GLP-1 + amylin (2 molecules)	Weekly injection	NDA filed Dec 2025
Amycretin	GLP-1 + amylin (1 molecule)	Weekly injection / oral	Phase 3 started Q1 2026
Retatrutide	GLP-1 + GIP + glucagon	Weekly injection	Phase 3 ongoing

Bottom Line

Amycretin is the most closely watched obesity drug entering Phase 3 in 2026, partly because its Phase 2 weight-loss numbers exceeded anything previously published. The mechanism is scientifically coherent; the unimolecular design is elegant. Phase 3 will determine whether the signal holds at scale and whether the safety profile is clean enough for broad approval.

Educational content only. Not medical advice.